Keytruda Wrongful Death Lawsuit Alleges Merck Failed to Warn About Fatal Immune Reactions

Jeffrey Dombeck died in September 2024 weeks after receiving his first Keytruda injection as part of melanoma treatment. His widow, Penny Dombeck, filed a wrongful death lawsuit against Merck alleging the drug's immune-checkpoint-inhibitor mechanism triggered severe auto-immune reactions that attacked her husband's heart, muscles, nerves, and kidney.

The complaint contends that Merck failed to provide adequate warnings about these auto-immune risks, particularly for patients with pre-existing health conditions that could be worsened by such reactions. The plaintiff argues that Merck prioritized profits over patient safety and that proper warnings could have prevented her husband's death.

Keytruda (pembrolizumab) is an immune checkpoint inhibitor approved by the FDA in 2014 for advanced melanoma and subsequently expanded to treat numerous cancer types. The lawsuit alleges Merck received thousands of reports of similar injuries over many years but only updated the drug's label after Dombeck's death, suggesting delayed regulatory response to known safety signals.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.